Skip to content
value.today
Poxel S.A. logo

Poxel S.A.

POXEL.PA
$22 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$7 M
For year ending December-2024
Net income
$-20 M
-275.9% margin
Official annual report (ESEF)
Employees
—

Poxel S.A. in brief

Poxel S.A. is a listed company in the Biotechnology industry, based in France. Its last known market value was $22 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $7 M and a net loss of $20 M. Its shares trade under the symbol POXEL.PA (EURONEXT).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Poxel S.A. timeline

2 events, 2009–2015
  1. 2009
  2. 🏁
    · approximate
    Incorporated as Poxel
  3. 2015
  4. •
    Legal Entity Identifier issued
    LEI 9695003OIX0T7NX72N26 registered.

Events of Poxel S.A. from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$108 M$215 M$323 M$431 M20202021202220232024

World rank over time

▼ down 16,361 places since 2020
2020-01-01: #12213#12,21320202021-01-01: #15101#15,10120212022-01-07: #20155#20,15520222022-12-25: #27377#27,37720222023-07-30: #28456#28,45620232024-01-05: #28574#28,5742024

Rank in France: #219 (Jan 2020) · #265 (Jan 2021) · #303 (Jan 2022) · #397 (Dec 2022) · #422 (Jul 2023) · #403 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-275.9%
Operating margin
-52.8%
Return on equity
—
Liabilities / assets
494.5%
Revenue growth
+235.5%
R&D / revenue
15.0%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2023: revenue $2M, net income $-38M$2MFY23Fiscal year ending Dec 2024: revenue $7M, net income $-20M$7MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$7M+235.5%$-4M$-20M-275.9%
Dec 2023$2M—$-31M$-38M-1772.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-10M——$-0.41—
Dec 2023$-15M——$-1.14—

Annual results

Revenue
$7 M
Operating income
$-4 M
Net income
$-20 M

For year ending December-2024 · source: official annual report (ESEF)

Balance sheet

Total assets
$16 M
Total liabilities
$77 M
Total equity
$-61 M

As of December-2024

Poxel S.A. scorecard#

Passes 2 of the 4 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • ✓Revenue grew in the newest year235.5%Revenue up 235.5% in fiscal 2024.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.41 vs -1.14Diluted EPS -0.41 in fiscal 2024 against -1.14 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 2
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2024.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median-52.8%-52.8% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Poxel S.A.'s statements, beside the median of Biotechnology.

Poxel S.A.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin-52.8%-60.5%
Net margin-275.9%-68.9%
Revenue growth235.5%15.8%

4of 6on the Piotroski tests of financial strength

  • Net loss of $20 million.
  • Shareholders' equity is negative: -$61 million.

Poxel S.A.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Poxel S.A.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue6,6361,98167413,3976,806
Cost of revenue2,9431,980672590
Gross profit3,6931.02.013,3396,806
Research and development1,00120,95313,94027,47929,219
Operating income−3,501−28,764−21,890−22,463−29,819
Interest and finance income1,8932481708681,722
Interest expense and finance costs14,0166,1489,9082,9501,727
Income before tax−18,303−35,088−31,396−23,760−31,794
Income tax2.02.02.02.036
Net income including minority interests−18,305−35,090−31,398−23,763−31,831
Earnings per share, basic-0.38-1.05-1.08-0.83-1.16
Earnings per share, diluted-0.38-1.05-1.08-0.83-1.16
Shares, weighted average (basic)4834292928
Balance sheet
Cash and cash equivalents3,6562,34113,05832,28740,203
Receivables4,61638539450281
Current assets14,8524,52016,57436,33745,964
Property, plant and equipment———1,7162,224
Other intangible assets2.01016,60616,63116,642
Non-current assets8330318,14018,55219,113
Total assets14,9354,82334,71454,88965,077
Current liabilities18,96513,28727,41915,90116,459
Non-current liabilities54,90140,61425,53730,78221,554
Total equity−58,931−49,078−18,2418,20627,065
Total liabilities and equity14,9354,82334,71454,88965,077
Cash-flow statement
Share-based compensation79−4482,8194,6032,794
Cash from operating activities−9,513−13,978−21,813−16,893−25,749
Capital expenditure——−11−28−235
Intangible assets bought——−12−21−46
Cash from investing activities92410−4252
Cash from financing activities10,7333,2302,5859,02528,712
Exchange-rate effect on cash3.0−10−1.0−4.00
Change in cash1,315−10,717−19,229−7,9153,016
ReportESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Poxel S.A. compares in Biotechnology

  • Revenue$7 M · higher than 39% of 647
  • Net margin-275.9% · higher than 21% of 408
  • Revenue growth235.5% · higher than 90% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Poxel S.A.🇫🇷$22 M—-275.9%+235.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 15, 2026

Figures from Official annual report (ESEF), value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Poxel S.A.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Poxel S.A.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Poxel S.A.? Suggest a correction